STAT
Members of Congress from both parties want the FDA to stop imports of copycat versions of Eli Lilly's experimental obesity drug, which is still in trials.
Recap by typeshit. Full story at STAT.
Bloomberg says the boom in GLP-1 use has opened a risky trade in weight loss drugs brought into Brazil illegally.
The pharmacy boards group, per InsideHealthPolicy, ties reported deaths linked to retatrutide to weak enforcement against gray-market peptide sellers.
Judge Raphael Leite Guedes in Maranhão found tirzepatide counts as a home-use drug under Law 9,656/98, even when a clinic gives the shots.
Inc. reports that some Georgia clinics are still marketing an unapproved Lilly weight loss drug even as the company moves against its sale.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
3:21
A short upload with no description, so the reasoning behind the claim isn't given. Worth a tap only if you follow the gray market retatrutide talk.
Loading…